

DAFTAR PUSTAKA

- Aboumarzouk, O.M., 2014. Extended spectrum beta-lactamase urinary tract infections. *Urology Annals*, **6**: 114–115.
- Adrizain, R., Suryaningrat, F., Alam, A., dan Setiabudi, D., 2018. Incidence of multidrug-resistant, extensively drug-resistant and pan-drug-resistant bacteria in children hospitalized at Dr. Hasan Sadikin general hospital Bandung Indonesia. *IOP Conference Series: Earth and Environmental Science*, **125**: 012077.
- Akram, M., Shahid, M., dan Khan, A.U., 2007. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Annals of Clinical Microbiology and Antimicrobials*, **6**: 4.
- Al-Garni, S.M., Ghonaim, M.M., Ahmed, M.M.M., Al-Ghamdi, A.S., dan Ganai, F.A., 2018. Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia. *Saudi Medical Journal*, **39**: 1186–1194.
- Amelia, A., Nugroho, A., dan Harijanto, P.N., 2016. Diagnosis and Management of Infections Caused by Enterobacteriaceae Producing Extended-Spectrum b-Lactamase. *Acta Med Indones*, **48**: 11.
- American Pharmacists Association, 2018. Lexicomp Drug Information Handbook - A Clinically Relevant Resource for All Healthcare Professionals, 26th ed. Wolters Kluwer.
- Anggraini, D., Sholihin, U.H., Savira, M., Djojosingito, F.A., Irawan, D., dan Rustam, R.P., 2018. Prevalensi dan Pola Sensitivitas Enterobacteriaceae Penghasil ESBL di RSUD Arifin Achmad Pekanbaru. *Jurnal Kedokteran Brawijaya*, **30**: 47.
- Arumugham, V.B. dan Cascella, M., 2020. Third Generation Cephalosporins, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Badan Pengawas Obat dan Makanan, 2014. *Informatarium Obat Nasional Indonesia (IONI)*.
- Bassetti, M., Vena, A., Croxatto, A., Righi, E., dan Guery, B., 2018. How to manage Pseudomonas aeruginosa infections. *Drugs in Context*, **7**: .
- Bauer, L.A., 2008. *Applied Clinical Pharmacokinetics*, 2nd ed. The McGraw-Hill Medical.
- Bird, S.T., Etmnan, M., Brophy, J.M., Hartzema, A.G., dan Delaney, J.A.C., 2013. Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ: Canadian Medical Association Journal*, **185**: E475–E482.
- Bochud, P.-Y., Bonten, M., Marchetti, O., dan Calandra, T., 2004. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. *the Society of Critical Care Medicine and Lippincott Williams & Wilkins*, **32**: .

- Bramantono, Purwati, dan Hamidah, 2013. The Prevalence Of Extended Spectrum Beta-Lactamase (ESBL) In Third Generation Cephalosporin Usage Among Sepsis Patients In The Department Of Internal Medicine RSUD Dr. Soetomo Surabaya. *Folia Medica Indonesiana*, **49**: 244–251.
- Carson, C. dan Naber, K.G., 2004. Role of Fluoroquinolones in the Treatment of Serious Bacterial Urinary Tract Infections: *Drugs*, **64**: 1359–1373.
- Centers for Disease Control and Prevention, n.d. Cancer, Infection and Sepsis Fact Sheet. 2.
- Chao, Y.-S. dan Farrah, K., 2019. *Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines*. Canadian Agency for Drugs and Technologies in Health.
- Chaudhary, R., 2016. Bacteriology of Urinary Tract Infection of Chronic Renal Failure Patients Undergoing for Hemodialysis. *Journal of Microbiology & Experimentation*, **3**: .
- Cho, S.-Y., Choi, S.-M., Park, S.H., Lee, D.-G., Choi, J.-H., dan Yoo, J.-H., 2016. Amikacin therapy for urinary tract infections caused by extended-spectrum β -lactamase-producing *Escherichia coli*. *The Korean Journal of Internal Medicine*, **31**: 156–161.
- Clinical and Laboratory Standards Institute, 2014. *M100-S24: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement*.
- Daef, A., Aly, S.A., El-Din, S.A.S., Sherbiny, N.M.E., dan El-Gendy, S.M., 2010. Phenotypic and Genotypic Detection of Extended Spectrum Beta Lactamase *Klebsiella Pneumoniae* Isolated from Intensive Care Units in Assiut University Hospital Enas.
- Dahesihdewi, A., 2014. Analisis Efektivitas Biaya Pilot Project Skrining Kolonisasi Methicillin-Resistant *Staphylococcus aureus* (MRSA) pada Pasien Ruang Intensif RSUP Dr Sardjito Yogyakarta.
- Dharma, I.G.G., Sukmawati, D.D., Gayatri, AAA.Y., Somia, I.K.A., Utama, M.S., dan Merati, T.P., 2015. Penatalaksanaan ESBL (Extended Spectrum Beta Lactamase). *Divisi Penyakit Tropik dan Penyakit Infeksi Lab/SMF Ilmu Penyakit Dalam FK Unud/RSUP Sanglah Denpasar*, .
- EAU Guidelines, 2013. GUIDELINES ON UROLOGICAL INFECTIONS. *EAU Guidelines, edition*, 21.
- Fahirah Arsal, A.St., Jafar, N., dan Arman, 2019. Deteksi dan Pola Kepekaan Antibiotik pada Extended Spectrum Beta Lactamase (Esbl) *Escherichia Coli* dari Sampel Urin Petugas Kesehatan di Rumah Sakit Ibnu Sina Makassar Tahun 2018. *UMI Medical Journal*, **3**: 1–13.
- Gandasoebrata, R., 2013. *Penuntun Laboratorium Klinis*. Dian Rakyat, Jakarta.
- Goering, R.V., Dockrell, H.M., Zuckerman, M., Wakelin, D., dan Roitt, I., 2008. *Mims Medical Microbiology*, 4th ed. ELSEVIER, England: Mosby UK.

- Guyton, A. dan Hall, J., 2016. *Buku Ajar Fisiologi Kedokteran*, 11th ed. Penerbit Buku Kedokteran EGC, Jakarta.
- Had, S., i, i, Amer, A., ustovi, ustovi, Smajlovi, J., dan Ahmetagi, S., 2012. Distribution of nosocomial infections caused by *Klebsiella pneumoniae* & ESBL strain. *Journal of Environmental and Occupational Science*, **1**: 141.
- Hadžić, S., Čustović, A., Smajlović, J., dan Ahmetagić, S., 2012. Distribution of nosocomial infections caused by *Klebsiella pneumoniae* ESBL strain. *Journal of Environmental and Occupational Science*, **1**: 141.
- Hakim, L., 2012. *Farmakokinetik Klinik : Konsep Untuk Rasionalisasi Regimen Dosis, Therapeutic Drug Monitoring, Konseling Pasien Dan Pengembangan Obat*. Bursa Ilmu, Yogyakarta.
- Handayani, R.S., Siahaan, S., dan Herman, M.J., 2018. Antimicrobial Resistance and Its Control Policy Implementation in Hospital in Indonesia. *Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan*, 131–140.
- Hassan, M., Tuckman, H.P., Patrick, R.H., Kountz, D.S., dan Kohn, J.L., 2010. Hospital length of stay and probability of acquiring infection. *International Journal of Pharmaceutical and Healthcare Marketing*, **4**: 324–338.
- Hoban, D.J., Nicolle, L.E., Hawser, S., Bouchillon, S., dan Badal, R., 2011. Antimicrobial susceptibility of global inpatient urinary tract isolates of *Escherichia coli*: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program: 2009–2010. *Diagnostic Microbiology and Infectious Disease*, **70**: 507–511.
- Hope, R., Warner, M., Potz, N. a. C., Fagan, E.J., James, D., dan Livermore, D.M., 2006. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from South-East England. *Journal of Antimicrobial Chemotherapy*, **58**: 1312–1314.
- Hsiao, C.-Y., Lin, H.-L., Lin, Y.-K., Chen, C.-W., Cheng, Y.-C., Lee, W.-C., dkk., 2014. Urinary tract infection in patients with chronic kidney disease. *TURKISH JOURNAL OF MEDICAL SCIENCES*, **44**: 145–149.
- IKATAN AHLI UROLOGI INDONESIA, 2015. Penatalaksanaan Infeksi Saluran Kemih dan Genitalia Pria 2015 106.
- Irawan, D. dan Ea, T., 2012. Profil Penderita Sepsis Akibat Bakteri Penghasil ESBL **13**: 6.
- Jorgensen, J.H. dan Ferraro, M.J., 2009. Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices. *Clinical Infectious Diseases*, **49**: 1749–1755.
- Kambuno, N.T. dan Fanggidae, D., 2017. Identification of Gram Negative Bacteria for Extended Spectrum Beta Lactamase Strains in NICU Room of RSUD Prof. DR. W. Z. Johannes Kupang. *Jurnal Info Kesehatan*, **15**: 13.

- Kang, D., Sinuraya, R.K., Rostinawati, T., dan Abdulah, R., 2017. Gene blaCTX-M Mutation as Risk Factor of Antibiotic Resistance. *Indonesian Journal of Clinical Pharmacy*, **6**: 135–152.
- Kelesidis, T., Karageorgopoulos, D.E., Kelesidis, I., dan Falagas, M.E., 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. *The Journal of Antimicrobial Chemotherapy*, **62**: 895–904.
- Kementerian Kesehatan Republik Indonesia, 2017a. 'Peningkatan Pelayanan Kefarmasian Dalam Pengendalian Resistensi Antimikroba "Apoteker Ikut Atasi Masalah Resistensi Antimikroba"', www.depkes.go.id. URL: <http://www.depkes.go.id/article/print/17111500002/peningkatan-pelayanan-kefarmasian-dalam-pengendalian-resistensi-antimikroba-apoteker-ikut-atasi-masa.html>.
- Kementerian Kesehatan Republik Indonesia, 2017b. 'KMK No. HK 01.07/MENKES/342/2017 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis.pdf', .
- Lee, N.-Y., Lee, C.-C., Huang, W.-H., Tsui, K.-C., Hsueh, P.-R., dan Ko, W.-C., 2013. Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters. *Clinical Infectious Diseases*, **56**: 488–495.
- Leekha, S., Terrell, C.L., dan Edson, R.S., 2011. General Principles of Antimicrobial Therapy. *Mayo Clinic Proceedings*, **86**: 156–167.
- Leistner, R., Schröder, C., Geffers, C., Breier, A.-C., Gastmeier, P., dan Behnke, M., 2015. Regional distribution of nosocomial infections due to ESBL-positive Enterobacteriaceae in Germany: data from the German National Reference Center for the Surveillance of Nosocomial Infections (KISS). *Clinical Microbiology and Infection*, **21**: 255.e1-255.e5.
- Martin, K.E., 2013. 'Treatment of ESBL-producing E coli Lower Urinary Tract Infection', *Pharmacy Times*. URL: <https://www.pharmacytimes.com/publications/health-system-edition/2013/november2013/treatment-of-esbl-producing-e-coli-lower-urinary-tract-infection> (diakses tanggal 10/11/2019).
- McDanel, J., Schweizer, M., Crabb, V., Nelson, R., Samore, M., Khader, K., dkk., 2017. Incidence of Extended-Spectrum β -Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. *Infection Control & Hospital Epidemiology*, **38**: 1209–1215.
- Mount Nittany Health Foundation, 2017. 'Extended-Spectrum Beta-Lactamase-ESBL-Producing Bacteria', . URL: <https://www.mountnittany.org/articles/healthsheets/10029> (diakses tanggal 10/11/2019).

- Muhajir, A., Purwono, P.B., dan Handayani, S., 2016. Gambaran Terapi dan Luaran Infeksi Saluran Kemih oleh Bakteri Penghasil Extended Spectrum Beta Lactamase pada Anak di RSUD Dr. Soetomo Surabaya. *Sari Pediatri*, **18**: 111.
- Munoz-Price, L.S., 2019. 'Extended-spectrum beta-lactamases', *UpToDate online*. URL: <https://www.uptodate.com/contents/extended-spectrum-beta-lactamases#H4> (diakses tanggal 4/8/2019).
- Naelasari, D.N., Koendhori, E.B., Dewanti, L., Sarassari, R., dan Kuntaman, K., 2018. The Prevalence of Extended Spectrum Beta-Lactamase (ESBL) Producing Gut Bacterial Flora Among Patients in Dr. Soetomo Hospital and Primary Health Centre in Surabaya. *Folia Medica Indonesiana*, **54**: 256.
- Pajariu, A., Firmanti, S.C., dan Isbandrio, B., 2010. 'Infeksi Oleh Bakteri Penghasil Extended-Spectrum Beta-Lactamase (ESBL) Di RSUP Dr.Kariadi Semarang: Faktor Risiko Terkait Penggunaan Antibiotik', . Fakultas Kedokteran Universitas Diponegoro, Semarang.
- Pana, Z.D. dan Zaoutis, T., 2018. Treatment of extended-spectrum β -lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now? *F1000Research*, .
- Paterson, D.L., Ko, W.-C., Von Gottberg, A., Casellas, J.M., Mulazimoglu, L., Klugman, K.P., dkk., 2001. Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β -Lactamases: Implications for the Clinical Microbiology Laboratory. *Journal of Clinical Microbiology*, **39**: 2206–2212.
- Peraturan Menteri Kesehatan Republik Indonesia Nomor 2406/MENKES/PER/XII/2011, 2011. Pedoman Umum Penggunaan Antibiotik.
- Public Health England, 2012. 'ESBLs – A threat to human and animal health? Report by the Joint Working Group of DARC and ARHAI', . Department of Health and Social Care of Public Health England.
- Public Health England, 2017. 'UK Standards for Microbiology Investigations Detection of Enterobacteriaceae producing extended spectrum β -lactamases', . Bacteriology B.59 Issue 4.1.
- Pullukcu, H., Tasbakan, M.I., Sipahi, O.R., Yamazhan, T., dan Ulusoy, S., 2008. Nitrofurantoin In The Treatment Of Extended-spectrum Beta-lactamase Producing E. Coli Related Lower Urinary Tract Infection. *Infectious Diseases Society of America*, .
- Rawat, D. dan Nair, D., 2010. Extended-spectrum β -lactamases in Gram Negative Bacteria. *Journal of Global Infectious Diseases*, **2**: 263–274.
- Rodríguez Baño, J., Navarro, M.D., Romero, L., Martínez Martínez, L., Muniain, M.A., Perea, E.J., dkk., 2004. Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing

- Escherichia coli* in Nonhospitalized Patients. *Journal of Clinical Microbiology*, **42**: 1089–1094.
- Rolston, K.V.I., 2017. Infections in Cancer Patients with Solid Tumors: A Review. *Infectious Diseases and Therapy*, **6**: 69–83.
- Rowe, T.A. dan Juthani-Mehta, M., 2013. Urinary tract infection in older adults. *Aging health*, **9**: .
- Sah, S.K., 2015. Extended spectrum Beta lactamase (ESBL) Mechanism of antibiotic resistance and Epidemiology. *International Journal of PharmTech Research*, **7**: 303–309.
- Santajit, S. dan Indrawattana, N., 2016. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. *BioMed Research International*, .
- Saravanan, M., Ramachandran, B., dan Barabadi, H., 2018. The prevalence and drug resistance pattern of extended spectrum β -lactamases (ESBLs) producing Enterobacteriaceae in Africa. *Microbial Pathogenesis*, **114**: 180–192.
- Schentag, J., Meagher, A., dan Forrest, A., 2003. Fluoroquinolone AUC Break Points and the Link to Bacterial Killing Rates Part 2: Human Trials. *The Annals of pharmacotherapy*, **37**: 1478–88.
- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S.Mohd.D., dan Kamal, M.A., 2015. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi Journal of Biological Sciences*, **22**: 90–101.
- Shakti, L. dan Veeraraghavan, B., 2015. Advantage and limitations of nitrofurantoin in multi-drug resistant Indian scenario. *Indian Journal of Medical Microbiology*, **33**: 477.
- Shakya, P., Shrestha, D., Maharjan, E., Sharma, V.K., dan Paudyal, R., 2017. ESBL Production Among and spp. Causing Urinary Tract Infection: A Hospital Based Study. *The Open Microbiology Journal*, **11**: 23–30.
- Singer, M., Deutchman, C., Seymour, W., Manu, S.-H., Djillali, A.D., dan Bellomo, R., 2016. The Third International Consensus Definitions for sepsis and septic shock (Sepsis-3). *JAMA*, , 315(8):804-6.
- Singh, B., Tilak, R., Srivastava, R.K., dan Katiyar, D., 2014. Urinary Tract Infection and its Risk Factors in Women: An Appraisal. *JOURNAL OF PURE AND APPLIED MICROBIOLOGY*, **9**.
- Tamma, P.D. dan Rodriguez-Baño, J., 2017. The Use of Noncarbapenem β -Lactams for the Treatment of Extended-Spectrum β -Lactamase Infections. *Clinical Infectious Diseases*, **64**: 972–980.
- Taneja, N., Rao, P., Arora, J., dan Dogra, A., 2008. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI. *The Indian Journal of Medical Research*, **127**: 85–88.

- Thalhammer, F. dan Horl, W.H., 2000. Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement Therapy: *Clinical Pharmacokinetics*, **39**: 271–279.
- Thomson, K.S. dan Moland, E.S., 2001. Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **45**: 3548–3554.
- Tulara, N.K., 2018. Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae. *Journal of Global Infectious Diseases*, **10**: 19–21.
- Udy, A.A., Roberts, J.A., dan Lipman, J. (Editor), 2018. *Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill*. Springer Singapore, Singapore.
- Utami, E.R., 2012. Antibiotika, Resistensi, dan Rasionalitas Terapi. *Saintis*, **1**: 15.
- Vardakas, K.Z., Tansarli, G.S., Rafailidis, P.I., dan Falagas, M.E., 2012. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*, **67**: 2793–2803.
- Wahyono, D., 2013. *Farmakokinetika Klinik, Konsep Dasar Dan Terapan Dalam Farmasi Klinik*. Gadjah Mada University Press, Yogyakarta.
- Wijayanti, A.D., Hakim, L., Widiyono, I., dan Irianti, T., 2010. Penentuan Efektifitas Oksitetrasiklin Melalui Parameter Farmakokinetik/farmakodinamik pada Plasma dan Jaringan Ayam Broiler **11**: 7.
- Winarto, 2009. Prevalensi Kuman ESBL (Extended Spectrum Beta Lactamase) dari Material Darah di RSUP Dr. Kariadi Tahun 2004-2005. *Media Medika Indonesiana*, **43**: 260–267.
- Winter, M.E., 1994. *Basic Clinical Pharmacokinetics*, 3rd ed. Vancouver.
- World Health Organization, 2016. 'WHO Surgical Site Infection Prevention Guidelines', . URL: <https://www.who.int/gpsc/appendix4.pdf?ua=1> (diakses tanggal 5/8/2019).
- World Health Organization, 2017. 'WHO publishes list of bacteria for which new antibiotics are urgently needed', *World Health Organization, Geneva, Switzerland*. URL: <https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed> (diakses tanggal 2/3/2019).